POLD2

Across TCGA pan-cancer cohorts, POLD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POLD2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher POLD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POLD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where POLD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.846	1.000	.007	18	view →
LSCC	OS	Quartile	II,III,IV	0.858	0.440	.005	10	view →
LUAD	DFS	Quartile	III,IV	0.881	0.368	.008	9	view →
PDAC	OS	Tertile	IV	0.490	0.973	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

POLD2–CCRCC (OS)

Open the CCRCC breakdown →